info@symbiosisip.co.uk

Journal Requests when publishing research

Author: Dr Julie Myint | julie@symbiosisip.co.uk

12 Aug 2020

#

Often when publishing your research you are asked to state that you have no conflict of interest in the publication. What does this mean and how should you respond?

Typically, conflicting interests, whether they be financial or non-financial, are interests that could undermine the objectivity, integrity or value of the publication, usually through influencing the judgements and actions of authors with regard to objective data presentation, analysis and interpretation.

Declaring a potential interest therefore helps readers form their own judgements about any potential bias. Normally, the corresponding author is responsible for submitting a competing interests’ statement on behalf of all authors of the paper.

Examples of conflicts of interest include scenarios where an author’s funding (including salaries, equipment, supplies, and other expenses) may be gained or lost through the publication; the funder has had a role in the design, data collection, data analysis, decision to publish, or preparation of the manuscript; employment of an author, present or anticipated, may result through the publication; an author’s stocks or shares in a company may rise or fall through publication; an author’s consultation fees may be affected by the publication; the value of an author’s patents or patent applications may be affected by the publication; an author has an paid/unpaid role in a government or non-governmental organization that relates to the research; the author is a member of an advocacy or lobbying organization relating to the research; the author has an advisory position in a commercial organization relating to the research; or the author acts/acted as an expert witness in relation to the research.

In terms of a financial conflict of interest, rather than operate on a given monetary threshold, it is often wise to consider whether the competing financial interests would embarrass you if it were to become publicly known after your work was published.

For the avoidance of doubt, typically, diversified mutual funds or investment trusts (pension funds) do not constitute a competing financial interest.

The interest can be declared in any of the following ways:

The authors declare the following competing interests: specified…

The authors declare the existence of a financial/non-financial competing interest.

The authors declare no competing interests.

The authors declare that they are bound by confidentiality agreements that prevent them from disclosing their competing interests in this publication.

"Lee Samuel readily understands technology and consistently demonstrates thorough knowledge of patent law, great attention to detail and efficient organisational skills, leading to successful grants."

IAM Patent 2022 Client Interview

"Andrew gave us the confidence that the final terms agreed were fair and in line with the current best practice"

UK University Head of Tech Transfer

"It is not an exaggeration to state that our confidence in Rob and Symbiosis is such that the strategic direction of our company has been IP-led at all times."

IAM Patent 2022 Client Interview

"Mark Hoggins consistently delivers excellent service and detailed and informed responses to examiners, and helps clients understand each step and grow in their understanding of the IP protection process."

IAM Patent 2022 Client Interview

"Excellent technical licensing and deal-making skills, [a] can-do attitude and an inherent sense of value to each assignment"

Senior Leader, Corporate

"Vast experience in commercialising science and technology"

Senior UK Patent Attorney

"Driven, dedicated and knowledgeable in the whole spectrum of work covering commercialisation of technology"

UK University Senior Tech Transfer

"Our two companies collaborate very well together to optimise the commercial benefits of the Glycologic Limited portfolio of activities."

Richard Tester
Managing Director, Glycologic Limited

"The work carried out by Symbiosis has always been of high quality. The team have a wealth of experience and understanding in life sciences, which means they are able to provide advice on patent filing from the earliest stage right through prosecution."

IAM Patent 2022 Client Interview

"Their communications are clear and always in good time for action to be taken. They have established a good network of foreign associates and we have recently had successful filings in the USA, Japan and China without a need for extensive office action and its associated costs."

IAM Patent 2022 Client Interview

"Result oriented, very responsive, a value creator and a person with a clear vision and strategy"

Senior Corporate Counsel

"Andrew lived up to our expectations, helping us take a very hard negotiation over the line. We enjoyed working with him and would do so again. I would definitely recommend him to organisations trying to navigate IP licensing negotiations"

UK CEO

"Symbiosis dives deep into the science and data and then gives an excellent assessment of the potential for the patent to be granted and the value of said patent."

IAM Patent 2022 Client Interview

"The service provided by Symbiosis is personal, efficient and highly professional."

IAM Patent 2022 Client Interview

"Julie always asks the right questions and grasps the heart of the invention easily. Julie expresses herself very clearly and it is straightforward to communicate with her, in both written and oral form. She presents commercial strategies, thanks to her long experience in the field and concrete exposure to challenges that she has been able to overcome."

IAM Patent 2022 Client Interview

"Symbiosis maximises the value of IP generated by our inventors in a cost effective and efficient manner that meets our commercial objectives."

Martin Whitaker
CEO, Diurnal

"Cardiff University has a longstanding relationship with Symbiosis IP and we have always experienced a consistently high quality range of IP services. We particularly appreciate the ability to provide bespoke advice for academic, TTO or industry audiences as appropriate and this has contributed significantly to our translational successes across the life sciences portfolio."

Rhodri Turner
Senior Technology Transfer Officer, Cardiff University

"It is a privilege to work with Symbiosis."

Prof. Richard Ross, CSO
Asterion Limited

"One of those rare breeds who manage to combine considerable technical expertise with a keen business sense"

Senior Leader, Corporate

Our use of cookies

We use necessary cookies to make our site work. We'd also like to set analytics cookies that help us make improvements by measuring how you use the site. These will be set only if you accept.

For more detailed information about the cookies we use, see our Cookies page. Cookie Control Link Icon


Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.